Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
about
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction RiskACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysmEnalapril improves endothelial function in patients with migraine: A randomized, double-blind, placebo-controlled trial.Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk ModelModulation of Vascular ACE by Oxidative Stress in Young Syrian Cardiomyopathic Hamsters: Therapeutic ImplicationsRAAS inhibition and mortality in hypertension.Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.Oxidative stress and early atherosclerosis: novel antioxidant treatment.Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine.The role of the endogenous antioxidant enzymes and malondialdehyde in essential hypertension.Perindopril for improving cardiovascular events.Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
P2860
Q28076223-2C6272E1-B43F-4097-9475-057701DA699FQ34634364-C45B2CD4-5DF4-4782-BAF7-948705E0E173Q34714052-8B702413-5840-4219-831B-FF1B6432FCF8Q37090714-B5A87837-B3EF-49FC-B49D-0312AA2A6E3BQ37128348-E8F8FDAB-4155-487F-AF38-87CF7A0678D0Q37659231-6C9F6A35-825A-44C8-AC5E-919CC62AF45FQ37798001-6EB55445-27CC-425A-BF01-8DE7E7597C56Q38005041-F25959EE-B561-43D6-9CB1-B7F15A4AE18CQ38113246-8F87C5D8-1ED3-429E-857F-9598A789B8AFQ38128175-391A335A-1FBA-4617-AF1A-6B11CACB23F1Q38175345-C092AFFA-E6C6-4489-8887-FB1759C49818Q38269619-3E1FC6F2-0A6D-48F2-959F-81AA2337E80DQ38852188-20D77F0C-0B08-4842-BADB-6A4FBB93DE96Q41812342-431CB863-B63C-44D6-AF94-ADC70AA0C242Q42864618-FA66A83B-61FD-4C3F-BF89-01F1A09EE606Q43945739-CF3DC0E1-F3F5-4893-88B9-CF75906A5558
P2860
Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insight into the mode of actio ...... : the ultimate 'EUROPA' story.
@en
Insight into the mode of actio ...... : the ultimate 'EUROPA' story.
@nl
type
label
Insight into the mode of actio ...... : the ultimate 'EUROPA' story.
@en
Insight into the mode of actio ...... : the ultimate 'EUROPA' story.
@nl
prefLabel
Insight into the mode of actio ...... : the ultimate 'EUROPA' story.
@en
Insight into the mode of actio ...... : the ultimate 'EUROPA' story.
@nl
P1433
P1476
Insight into the mode of actio ...... : the ultimate 'EUROPA' story.
@en
P2093
Roberto Ferrari
P304
P356
10.2165/00003495-200969030-00003
P577
2009-01-01T00:00:00Z
P6179
1024922640